Insider · CIK 0001694466
David J. Mack
Files at BTAIQ (BioXcel Therapeutics, Inc.). First filing -, latest -.
In brief
David J. Mack files SEC Form 4 as director at BTAIQ (BioXcel Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David J. Mack has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 28 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Oct 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,694 | - | - | 20,317 | Nov 3, 2025 |
| Oct 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,694 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Sep 30, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,694 | - | - | 18,623 | Oct 1, 2025 |
| Sep 30, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,694 | $0.00 | $0 | 1,694 | Oct 1, 2025 |
| Aug 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,693 | - | - | 16,930 | Sep 2, 2025 |
| Aug 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 3,387 | Sep 2, 2025 |
| Jul 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,693 | - | - | 15,237 | Jul 31, 2025 |
| Jul 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 5,080 | Jul 31, 2025 |
| Jun 30, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,693 | - | - | 13,544 | Jun 30, 2025 |
| Jun 30, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 6,773 | Jun 30, 2025 |
| May 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,693 | - | - | 11,851 | Jun 2, 2025 |
| May 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 8,466 | Jun 2, 2025 |
| Apr 30, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,693 | - | - | 10,158 | May 1, 2025 |
| Apr 30, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 10,159 | May 1, 2025 |
| Mar 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,693 | - | - | 8,465 | Apr 1, 2025 |
| Mar 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 11,852 | Apr 1, 2025 |
| Feb 28, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +1,693 | - | - | 6,772 | Mar 4, 2025 |
| Feb 28, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 13,545 | Mar 4, 2025 |
| Jan 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +27,089 | - | - | 81,267 | Feb 4, 2025 |
| Jan 31, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -27,089 | $0.00 | $0 | 243,810 | Feb 4, 2025 |
| Dec 31, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +27,089 | - | - | 54,178 | Jan 3, 2025 |
| Dec 31, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | +27,089 | $0.00 | $0 | 270,899 | Jan 3, 2025 |
| Nov 30, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +27,089 | - | - | 27,089 | Dec 4, 2024 |
| Nov 30, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -27,089 | $0.00 | $0 | 297,988 | Dec 4, 2024 |
| Nov 30, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +27,089 | - | - | 27,089 | Dec 3, 2024 |
| Nov 21, 2024 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative10b5-1 | +297,988 | $0.00 | $0 | 297,998 | Dec 3, 2024 |
| Nov 21, 2024 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +325,077 | $0.00 | $0 | 325,077 | Nov 25, 2024 |
Questions about David J. Mack
Answered from the filings on this page, as of the latest one.
Is David J. Mack buying or selling?
David J. Mack has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David J. Mack's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David J. Mack has 0.
Where does David J. Mack file Form 4?
David J. Mack has filed Form 4 at BTAIQ (BioXcel Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.